Erratum: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (Clin Cancer Res (2022) 28 (57–70) DOI: 10.1158/1078-0432.CCR-21-2160)

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror

Research output: Contribution to journalComment/debate

Fingerprint

Dive into the research topics of 'Erratum: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (Clin Cancer Res (2022) 28 (57–70) DOI: 10.1158/1078-0432.CCR-21-2160)'. Together they form a unique fingerprint.

Medicine & Life Sciences